Drug Profile
Research programme: liver X receptor modulators - Bristol-Myers Squibb/Exelixis
Alternative Names: EXEL 2255; LXR modulatorsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Exelixis
- Developer Bristol-Myers Squibb; Exelixis
- Class Small molecules
- Mechanism of Action Liver X receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atherosclerosis; Hypercholesterolaemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Atherosclerosis in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hypercholesterolaemia in USA (PO)
- 13 Oct 2010 Bristol-Myers Squibb and Exelixis make undisclosed minor amendments to their LXR agreement